Tomoko Yoshihama1, Yuka Kuroda1,2, Tatsuyuki Chiyoda3, Mio Takahashi1, Takuma Yoshimura1, Keiko Saotome1,4, Yoshiko Nanki2, Kensuke Sakai1, Yusuke Kobayashi1, Wataru Yamagami1, Daisuke Aoki1. 1. Department of Obstetrics and Gynecology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. 2. Department of Obstetrics and Gynecology, Inagi Municipal Hospital, Tokyo, Japan. 3. Department of Obstetrics and Gynecology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. chiyoda@keio.jp. 4. Department of Obstetrics and Gynecology, Eiju General Hospital, Tokyo, Japan.
Abstract
BACKGROUND: Olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer has been approved in Japan since April 2018. Here, we report the experience administering this therapy in our hospital, with the aim of evaluating efficacy and safety in the Japanese population. METHODS: The study included 52 patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer. All patients started olaparib at a dose of 300 mg twice daily. Information about treatment efficacy and adverse effects was collected retrospectively from medical records. RESULTS: Median age was 58 years old (range: 33-80), and 82.7% of the patients were diagnosed with high-grade serous carcinoma. Sixteen patients (30.8%) possessed the BRCA1/2 pathogenic variant (15 germline and 1 tissue), 3 (5.8%) possessed variants of unknown significance (2 germline and 1 tissue), 16 (30.8%) possessed wild type, and 17 (32.7%) were not analyzed. Median progression-free survival was 15.3 months (95% CI 9.0-21.6). Patients with BRCA1/2 pathogenic variants showed significantly longer PFS than patients with wild-type BRCA1/2 (p = 0.007). Disease progression caused 34 cases to discontinue olaparib. Eighteen (34.6%) individuals exhibited ≥ grade 3 anemia, although they recovered in response to appropriate management. One patient discontinued olaparib because of prolonged renal dysfunction. Another patient presented with grade 3 fatigue, but recovered after 2 weeks of interruption and continued olaparib treatment. CONCLUSION: Olaparib maintenance therapy for platinum-sensitive recurrent ovarian cancer in the Japanese population is sufficiently safe and no less effective than reports from previous studies.
BACKGROUND: Olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer has been approved in Japan since April 2018. Here, we report the experience administering this therapy in our hospital, with the aim of evaluating efficacy and safety in the Japanese population. METHODS: The study included 52 patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer. All patients started olaparib at a dose of 300 mg twice daily. Information about treatment efficacy and adverse effects was collected retrospectively from medical records. RESULTS: Median age was 58 years old (range: 33-80), and 82.7% of the patients were diagnosed with high-grade serous carcinoma. Sixteen patients (30.8%) possessed the BRCA1/2 pathogenic variant (15 germline and 1 tissue), 3 (5.8%) possessed variants of unknown significance (2 germline and 1 tissue), 16 (30.8%) possessed wild type, and 17 (32.7%) were not analyzed. Median progression-free survival was 15.3 months (95% CI 9.0-21.6). Patients with BRCA1/2 pathogenic variants showed significantly longer PFS than patients with wild-type BRCA1/2 (p = 0.007). Disease progression caused 34 cases to discontinue olaparib. Eighteen (34.6%) individuals exhibited ≥ grade 3 anemia, although they recovered in response to appropriate management. One patient discontinued olaparib because of prolonged renal dysfunction. Another patient presented with grade 3 fatigue, but recovered after 2 weeks of interruption and continued olaparib treatment. CONCLUSION: Olaparib maintenance therapy for platinum-sensitive recurrent ovarian cancer in the Japanese population is sufficiently safe and no less effective than reports from previous studies.
Authors: J Mateo; V Moreno; A Gupta; S B Kaye; E Dean; M R Middleton; M Friedlander; C Gourley; R Plummer; G Rustin; C Sessa; K Leunen; J Ledermann; H Swaisland; A Fielding; W Bannister; S Nicum; L R Molife Journal: Target Oncol Date: 2016-06 Impact factor: 4.493
Authors: Eric Pujade-Lauraine; Jonathan A Ledermann; Frédéric Selle; Val Gebski; Richard T Penson; Amit M Oza; Jacob Korach; Tomasz Huzarski; Andrés Poveda; Sandro Pignata; Michael Friedlander; Nicoletta Colombo; Philipp Harter; Keiichi Fujiwara; Isabelle Ray-Coquard; Susana Banerjee; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Patricia Pautier Journal: Lancet Oncol Date: 2017-07-25 Impact factor: 41.316
Authors: L C Hanker; S Loibl; N Burchardi; J Pfisterer; W Meier; E Pujade-Lauraine; I Ray-Coquard; J Sehouli; P Harter; A du Bois Journal: Ann Oncol Date: 2012-08-21 Impact factor: 32.976
Authors: Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Euan Macpherson; Claire Watkins; James Carmichael; Ursula Matulonis Journal: N Engl J Med Date: 2012-03-27 Impact factor: 91.245